HbA o . This analyzer system denoted the chromatogram as abnormal separation. This HPLC method uses cation-exchange and reversed-phase chromatography on a solid phase of methacrylic acid and methacrylate ester. The hemoglobin fractions are eluted by varying the pH of the mobile phase.
The mean blood glucose of our patient was near the upper limit if the reference interval is at 7 mmol/L (126 mg/dL), based on a mean of 3-4 daily home measurements during 1 week before HbA 1c evaluation. The serum fructosamine was 256 mol/L (reference values Ͻ285 mol/L). Electrophoretic analysis on cellulose acetate membranes (Helena Laboratories) of a blood sample from our patient revealed an abnormal hemoglobin anodal to HbS. Citrate agar electrophoresis of hemoglobin using citrate buffer at pH 6.2 demonstrated a hemoglobin variant co-migrated with HbA. Identification of HbD was performed with the ␤-Globin StripA ssay (Vienna Lab) using reverse-hybridization with the patient's amplified DNA and probes for HbD. Routine hematological indices were within reference values.
We conclude that HbD, a common hemoglobinopathy (4), may cause diagnostic confusion because of falsely low and high HbA 1c values when measured by these two HPLC methods. This supports the suggestion that fructosamine measurement is a suitable alternative to control diabetes in patients with hemoglobin variants (5) .
*Author for correspondence. Fax 43-316-385-3062; e-mail wolfgang.schnedl@ kfunigraz.ac.at.
Determination of Cerebrospinal Fluid Glucose with the Vitros DT60 II Dry Chemistry System
To the Editor:
The steadily growing number of neurometabolic disorders has led to an increased use of cerebrospinal fluid (CSF) for the analysis of special metabolites such as amino acids, organic acids, and neurotransmitters, apart from the traditional routine investigations of cell count, glucose, and protein content. Because in young children the volume of CSF available for these investigations is restricted, minimization of routine procedures becomes important. We have therefore compared a dry chemistry method for the determination of glucose (1) with the traditional routine glucose oxidase method (GOD-Perid method) used in our laboratory (2) .
The Vitros dry chemistry system has glucose determinations for CSF only available for automated analyzers (Vitros 250, 500, 700, and others). The glucose slides for the manual DT60 II are intended only for plasma/serum glucose determination. The reason for this limitation is not quite clear because the test principle is the same in the slides for the DT60 II and the automated analyzers. ␤-d-Glucose is oxidized to d-gluconic acid by glucose oxidase. Hydrogen peroxide, which is simultaneously produced, reacts with 4-aminoantipyrine and 1,7-dihydroxynaphthalene to form a red dye.
We have compared the CSF glucose determination using the Vitros DT60 II system (Johnson & Johnson Clinical Diagnostics, Inc.) with the The difference in glucose concentration is plotted against the average glucose concentration determined by the two methods (3). Mannheim) that is routinely used in our laboratory. All determinations were performed in duplicate with 10 L of CSF on the DT60 II and 100 L for the GOD-Perid method.
GOD-Perid method (Boehringer
For this study 185 unselected, consecutive samples were analyzed. The mean difference for these two methods (Vitros DT60 II Ϫ GOD Perid) lies at Ϫ0.1 mmol/L (Ϫ1.8 mg/dL), with an SD of 0.39 mmol/L (7.0 mg/ dL) ( Fig. 1) . Linear regression statistics are as follows: (numbers in parentheses are for conventional units) slope, 1.076; intercept, Ϫ0.120 (Ϫ2.16); S y͉x , 0.361 (6.58); correlation coefficient, 0.935. Ten of the samples gave no value on the DT60 II [below the detection limit; Ͻ1.0 mmol/L (18 mg/dL)] and had to be excluded from the calculation.
The DT60 II seems to give somewhat higher values in the low range [Ͻ2 mmol/L (36 mg/dL)]; however, no trend can be seen on the whole. The picture in the low range might also be distorted because the two methods do not have the same detection limit. Therefore, samples in the low range where the difference would be negative cannot be calculated because they cannot be measured with the DT60 II. The DT60 II system appears to provide a reliable, accurate, and rapid method for determination of CSF glucose. 
Ralph Fingerhut * University of Hamburg Department of Pediatrics D-20246 Hamburg, Germany

Comment on the Nature and Specificity of Bayer Corporation and Chiron Diagnostics hCG Immunoassays
We wish to update information in the recent hCG review article (1), regarding the specificities and antibody configurations used in the Chiron Diagnostics and Bayer Corporation hCG immunoassays.
The review article depicted the diverse nature of the human chorionic gonadotropin (hCG) molecule. As described, a non-nicked hCG (the hormone), a nicked hCG, a free ␣-subunit, and a free ␤-subunit are present in blood samples, and the same molecules plus a ␤-core fragment occur in urine samples.
As described in the review article (1), commercial hCG assays sold in the United States use a variety of antibodies directed to different sites on hCG and related molecules. Some assays use antibodies to non-nicked hCG ("anti-hCG dimer"), others use antibodies to sites on hCG ␤-subunit common to hCG and its free ␤-subunit ("anti-common ␤1" and "anticommon ␤2"). Still other assays use antibodies to diverse epitopes on hCG subunits and fragments ("anticommon ␣", "anti ␤ C-terminal", "anti-free ␤", and "anti ␤-core fragment"). The combination of antibodies used by an hCG assay dictate the specificity of the assay and whether it detects non-nicked hCG only, nonnicked hCG and free ␤-subunit, nicked and non-nicked hCG only, or nicked and non-nicked hCG with free ␤-subunit and possibly ␤-core fragment.
In Table 2 of the review article, examples were given of antibody configurations and of the likely specificities of 54 commercial hCG-related immunoassays sold in the United States (1). The table was based totally on information in assay instruction booklets, on details from telephone technical support services, and on information published in reports. Here we make corrections to that table.
The Chiron Diagnostics Magic Lite TM total hCG assay uses a combination of anti-common ␤2 and anti-hCG dimer antibodies to capture antigens and an anti-common ␤1 antibody to label the captured molecules. This combination of antibodies detects nicked and non-nicked hCG, free ␤-subunit and urine ␤-core fragment, or all hCG␤-related molecules. The Chiron Diagnostics ACS:180 TM assay uses the same types of antibody, but with the capture and tracer antibodies reversed (anti-common ␤1 capture antibody, with anti-common ␤2 and anti-hCG dimer tracer antibodies). This assay also detects nicked and non-nicked hCG and free ␤-subunit. It does not detect urine ␤-core fragment. The Bayer Corporation Immuno-1 TM hCG assay uses a similar mixture of antibodies. It uses a combination of an anti-common ␤2 and anti-hCG dimer antibody to capture hCG and related molecules and an anti-common ␤1 antibody to label captured molecules. This assay also detects nicked and non-nicked hCG and free ␤-subunit. The table in the review article also listed a Bayer Immuno-1 ␤-core fragment assay (1). This assay is strictly a research assay and is not for sale.
As described in this and other review articles by Dr. Cole (1-3) , detection of nicked hCG, hCG missing the ␤-subunit C-terminal, and free ␤-subunit may be important for monitoring hCG immunoreactivity in patients with trophoblast disease, in patients with cancer, for pregnant women with aneuploid fetuses, and for following the clearance of hCG after parturition or termination of pregnancy. The Chiron Diagnostics Magic Lite and the Chiron Diagnostics ACS:180 total hCG assays and the Bayer Immuno-1 hCG assay detect these important hCG-related molecules and may be useful for these pregnancy-and cancer-related applications.
